Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
Phase 4
Completed
- Conditions
- Esophageal Cancer
- Registration Number
- NCT00911092
- Lead Sponsor
- Centre Oscar Lambret
- Brief Summary
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
- Detailed Description
Further informations will be provided by Centre Oscar Lambret.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
- Treated by exclusive concomitant radiochemotherapy
- Written informed consent
Exclusion Criteria
- Presence of a second uncontrolled cancer
- Metastatic carcinoma
- Metastatic disease, except cervical lymphnodes... (M1a)
- In situ carcinoma
- Eso-gastric junction cancer (Siewert II ou III)
- Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry 15 weeks after the end of irradiation Initial complete clinical response 15 weeks after the end of irradiation
- Secondary Outcome Measures
Name Time Method Prolonged clinical response at one year One year after the end of irradiation
Trial Locations
- Locations (6)
Centre Paul Papin
🇫🇷Angers, France
Centre François BACLESSE
🇫🇷Caen, France
Centre Oscar Lambret
🇫🇷Lille, France
Centre Eugène Marquis
🇫🇷Rennes, France
CHU - Hopital Charles Nicolle
🇫🇷Rouen, France
Centre Hospitalier Universitaire
🇫🇷Brest, France